The US Food and Drug Administration (FDA) today announced the approval of Recarbrio, a new three-drug antibacterial product developed by Merck, for treating patients with complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs) caused by gram-negative pathogens.
The number of confirmed and probable cases of the multidrug-resistant fungus Candida auris in the United States rose to 716 as of May 31, reflecting an increase of 32, the US Centers for Disease Control and Prevention (CDC) said in its most recent case-count update.
To control the deadly fungus, scientists have to better understand how it spreads.
The Nebraska Department of Health and Human Services (NDHHS) yesterday issued a health alert about an increase in carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) cases this year. After detecting 7 each year in 2017 and 2018, officials have already confirmed 12 CP-CRE infections so far this year.
A study yesterday in BMC Infectious Diseases by Pakistani researchers describes the wide range of invasive infections and high mortality rate associated with the multidrug-resistant fungus Candida auris.
Implementation of an antimicrobial stewardship program intervention at 27 nursing homes in North Carolina was associated with reductions in urine culture and culture-positive rates, according to a study today in Infection Control and Hospital Epidemiology. But high proportions of antimicrobial resistance were still observed among common urinary pathogens.
Confirmed and probable Candida auris cases in the United States through Mar 31 rose to 643, an increase of 56 from the end of February, the Centers for Disease Control and Prevention (CDC) said in an update yesterday.
Though success has been shown in only 2 patients, recruitment of more patients is under way.
Experts from the US Centers for Disease Control and Prevention (CDC) estimated yesterday in Antimicrobial Resistance & Infection Control that establishing nationwide antibiotic stewardship programs to prevent Clostridioides difficile infections in hospitals would result in an annual net benefit of $25.5 billion.
Staphylococcus aureus hospitalizations at US pediatric hospitals fell by 36% from 2009 to 2016, with methicillin-resistant S aureus (MRSA) declining by 52%, with a corresponding drop in antibiotic use, according to a study today in Infection Control and Hospital Epidemiology.
